Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, Q1 came close to matching the final quarter of last year, when 21 of the top 25 companies showed increases.

Biopharma 312

Biopharma Pharma 312

MedCity News

MAY 16, 2024

While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center. The post Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says appeared first on MedCity News.

Healthcare 133

Healthcare Healthcare Patients 133

Fierce Pharma

MAY 16, 2024

China-made PD-1 inhibitors just can’t get a clean pass through the FDA. | China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer.

FDA 311

FDA Pharma 311

MedCity News

MAY 16, 2024

The dangers of polypharmacy and its increasingly wide reach across the American population make it imperative that we enhance the accuracy and efficiency of medication reconciliation processes. The post It’s Past Time to Prevent Polypharmacy in U.S. Healthcare appeared first on MedCity News.

Healthcare 130

Healthcare Healthcare Medical 130

Advertisement

Fierce Pharma

MAY 16, 2024

A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansi | A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansion to boost capacity for its blockbuster diabetes and obesity drugs.

Manufacturing 298

Manufacturing 298

MedCity News

MAY 16, 2024

Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation. The post J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition appeared first on MedCity News.

Biopharma 111

Biopharma Pharma 111

MedCity News

MAY 16, 2024

Virginia Medicaid beneficiaries now have access to Aeroflow Health’s breast pumps and lactation consultants. The post Virginia Medicaid Taps Aeroflow Health for Lactation Services appeared first on MedCity News.

Consulting 109

Consulting 109

Fierce Pharma

MAY 16, 2024

After admitting to the crime four years ago, a former Sandoz executive will avoid hard time for his part in a generic drug price-fixing scheme. | Hector Kellum agreed to cooperate with federal investigators in 2020, admitting his part in a massive generics price-fixing scheme that spanned many companies.

263

263

MedCity News

MAY 16, 2024

At the MedCity INVEST conference from May 21-22 at the Ritz Carlton in Chicago, a panel discussion sponsored by Quantum Health will share how employers are addressing value-based care. The post Employers Will Share Value-Based Care Strategies at MedCity INVEST appeared first on MedCity News.

98

98

Fierce Pharma

MAY 16, 2024

The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer, where the CD19 CAR-T will again compete with Gilead Sciences and Novartis drugs.

FDA 182

FDA 182

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

MAY 16, 2024

Notable biotech financings in the last week include a $120m direct offering for iTeos, and private rounds for Lycia, Attovia, Ajax, and CinDome

113

113

Pharmaceutical Technology

MAY 16, 2024

The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.

Distribution 105

Distribution 105

PharmaTimes

MAY 16, 2024

The cardiovascular disease, pulmonary arterial hypertension, affects around 6,500 people in the UK

Patients 110

Patients 110

Pharmaceutical Technology

MAY 16, 2024

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Hypopharyngeal Cancer.

Pharmaceutical 98

Pharmaceutical 98

Advertisement

Distribution

PharmaTimes

MAY 16, 2024

The OptiZest study aims to investigate a personalised dose of Zestril in these patients

Medicine 112

Medicine Patients Medical 112

Pharmaceutical Technology

MAY 16, 2024

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Oropharyngeal Cancer.

Pharmaceutical 98

Pharmaceutical 98

European Pharmaceutical Review

MAY 16, 2024

GSK’s funding would be accessible for approved projects including those that employ new technology such as AI to improve interpretation and use complex scientific data” GSK is set to become the first founding partner of the Fleming Initiative. According to GSK, The Fleming Initiative’s will gather “world-class scientific, technology, policy and behavioural science expertise with clinical experience in a global network of centres to find, test, and scale solutions to [antimicrobial resistan

Networking 74

Networking Pharmaceutical Pharma Healthcare 74

Pharmaceutical Technology

MAY 16, 2024

Docetaxel albumin bound is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Laryngeal Cancer.

Pharmaceutical 98

Pharmaceutical 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

European Pharmaceutical Review

MAY 16, 2024

Matthew Shields has been appointed as Executive Vice President of Teva Pharmaceutical Industries Ltd.’s manufacturing and supply division. His position within Teva Global Operations will commence on 3 June 2024. He will be part of the company’s Executive Leadership Team and be based at Teva’s US headquarters. Mr Shields stated that he is “honoured” to take on his new role.

Engineering 70

Engineering Manufacturing Pharmaceutical Healthcare 70

Pharmaceutical Technology

MAY 16, 2024

Chenodiol is under clinical development by Leadiant Biosciences and currently in Phase II for Cerebrotendinous Xanthomatosis.

98

98

pharmaphorum

MAY 16, 2024

Roche reports promising data with obesity candidate CT-388, bought as part of its $3.

108

108

Pharmaceutical Technology

MAY 16, 2024

DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Melanoma.

97

97

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Copyright Clearance Center

MAY 16, 2024

May 16, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, was named a Bronze Stevie® Award winner for Customer Service Department of the Year in the 22nd annual American Business Awards ®. The American Business Awards are the premier business awards program in the U.S. Nicknamed the “Stevies” for the Greek word meaning “crowned,” the competition receives over 12,000 entries each year from organizations in 70 countries.

Competition 59

Competition Education Sales 59

Pharmaceutical Technology

MAY 16, 2024

INZ-701 is under clinical development by Inozyme Pharma and currently in Phase II for Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome).

Pharma 75

Pharma 75

Pharmaceutical Commerce

MAY 16, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

Pharmaceutical Technology

MAY 16, 2024

There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.

81

81

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Clarify Health

MAY 16, 2024

Chief Strategy Officers (CSOs) for health systems face the constant challenge of finding new revenue streams to cover the increasing costs of high- quality healthcare. To help tackle the problem, they are turning to predictive analytics for deep insights that can drive strategic decisions and open new revenue channels. By leveraging predictive analytics, CSOs can identify under-served areas, develop new service lines, enhance telemedicine offerings, and foster partnerships and collaborative ve

Healthcare 52

Healthcare Healthcare Healthcare Provider Specialization 52

Contrarian Sales Techniques

MAY 16, 2024

I still remember the day vividly – it was a rainy Tuesday afternoon, and I was scheduled for a pharmaceutical sales call that I had been dreading for weeks. My client was known for being tough, and I had rehearsed my pitch countless times. Little did I know, this particular call would turn out to be a turning point in my career, teaching me invaluable lessons about the art of conversation and the true essence of building relationships in the pharmaceutical industry.

Pharmaceutical Sales 52

Pharmaceutical Sales Sales Pharmaceutical Side effects 52

PharmExec

MAY 16, 2024

In an interview with Pharm Exec Associate Editor Don Tracy at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses the use of artificial intelligence and machine learning in drug development.

Pharma 52

Pharma FDA 52

LEVO Health

MAY 16, 2024

Voice search is changing the way consumers find information, and it’s quickly becoming a staple in the daily lives of patients. In healthcare marketing, staying ahead means embracing this technology to ensure patients can easily find your services. With a significant portion of the U.S. population now using voice-activated devices to ask health-related questions or locate nearby medical facilities, optimizing for voice search is not just beneficial — it’s essential.

Healthcare 52

Healthcare Healthcare Marketing Engineering 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization